"and todays Q announcement clearly reflects that not only were the bio-studies costs absorbed in August...CEO Odidi specifically states that they're currently satisfying the FDA's Focalin bioequivalence requirements!"
Thanks for pointing that out, was reading on my phone this morning and missed it.